SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 13, 2018
DARÉ BIOSCIENCE, INC.
(Exact name of registrant as specified in charter)
(State or other jurisdiction of
|(Commission File Number)|| |
|3655 Nobel Drive, Suite 260|
|San Diego, California||92122|
|(Address of principal executive offices)||(Zip Code)|
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☑
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☑
|Item 5.02|| |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On and effective as of September 13, 2018, the Board of Directors (the Board) of Daré Bioscience, Inc. (Daré), upon recommendation of Darés Nominating and Corporate Governance Committee, increased the size of the Board from six to seven directors and elected Greg W. Matz to fill the vacancy created by such increase. The Board appointed Mr. Matz as a member of the Audit Committee. Mr. Matz was elected as a Class II director and his term expires at Darés 2019 annual meeting of stockholders. The Board determined that Mr. Matz is an independent director under Rule 5605(a)(2) of the Nasdaq Listing Rules and met the other Nasdaq Listing Rules criteria to serve on the Audit Committee.
Until he retired in November 2016, Mr. Matz served as the Senior Vice President, Chief Risk Officer and Chief Financial Officer for The Cooper Companies, offices he held from November 2014, November 2013 and December 2011, respectively. He served as Vice President of The Cooper Companies from December 2011 to November 2013 and as its Vice President, Finance from July 2011 to December 2011. He joined CooperVision, Inc. in May 2010 as Vice President and Chief Financial Officer and served in that position until October 2011. Prior to joining CooperVision, he spent 25 years in the electronic measurement, chemical analysis and life science markets. He served in a variety of senior management roles with Agilent Technologies Inc. from 1999 to 2010, including Vice President and Controller of the Wireless Business Unit, Vice President and Director of Internal Audit and Assistant Corporate Controller. Prior to Agilent, Mr. Matz worked at Hewlett Packard from 1984 to 1999 in a variety of financial and marketing roles. Mr. Matz started his career at KPMG in San Francisco from 1981 to 1984. Mr. Matz is a Certified Public Accountant and graduated from the University of San Francisco with a B.S. in Business and the University of Pennsylvania, The Wharton Schools Advanced Management Program.
There are no arrangements or understandings between Mr. Matz and any other person pursuant to which he was selected as a member of the Board. Daré is not aware of any transaction in which Mr. Matz has an interest requiring disclosure under Item 404(a) of Regulation S-K.
In accordance with Darés non-employee director compensation policy, in connection with his election to the Board, Mr. Matz was granted a stock option to purchase 45,000 shares of Darés common stock, which has an exercise per share equal to the stocks closing price on the grant date and which will vest as to one-third of the shares on each anniversary of the grant date until the third anniversary thereof. Also, in connection with his election to the Board, Daré will enter into an indemnification agreement with Mr. Matz in the same form that Daré has entered into with its other directors.
|Item 7.01|| |
Regulation FD Disclosure
Daré issued a press release announcing the election of Mr. Matz to the Board, a copy of which is attached as an exhibit to this report.
The information contained in this Item 7.01 and Exhibit 99.1 to this report shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any filings made by Daré under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
|Item 9.01.|| |
Financial Statements and Exhibits.
|Press release issued on September 17, 2018|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|DARÉ BIOSCIENCE, INC.|
|Date: September 17, 2018||By:|
|Name:||Sabrina Martucci Johnson|
|Title:||President and Chief Executive Officer|
Greg Matz Joins Daré Bioscience Board of Directors
SAN DIEGO, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, womens biopharmaceutical company, today announced the appointment of Greg Matz to its board of directors. Most recently, Mr. Matz served as the Senior Vice President and Chief Financial Officer for The Cooper Companies, which includes CooperSurgical, marketers of PARAGARD®, the only hormone-free, long lasting, reversible contraceptive approved by the United States Food and Drug Administration available in the United States.
Greg brings a broad and diverse skill set that includes organizational development and strategic planning for a global medical device company, said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. Greg is well suited to help Daré execute on its vision of becoming a coordinating presence in womens health and we are excited to add him to our highly distinguished board of directors during this important and transformational stage in Dares corporate evolution.
The Cooper Companies is a publicly traded, global medical device company that operates through two business units, CooperVision and CooperSurgical. The CooperSurgical business focuses on advancing the health of families through a diversified portfolio of products and services focusing on womens health, fertility, diagnostics and contraception. The company has over 11,000 employees with products sold in over 100 countries. In his role as CFO, Mr. Matz provided leadership for the financial functions including planning, reporting, tax, audit, business analytics and risk management. In addition, he closely partnered with the executive team on global strategy, M&A, investor relations and business development activities.
Prior to his role as CFO with The Cooper Companies, Mr. Matz was CFO at CooperVision Inc., where he led global finance and information technology and managed a team of over 400 people. Prior to these roles, Mr. Matz served in a variety of senior-level positions for Agilent Technologies including Business Unit Controller, Vice
President of Global Audit Services and Controller for Mergers, Acquisitions & Divestitures. Before joining Agilent, Mr. Matz held management positions at Hewlett Packard and KPMG.
Daré is quickly becoming an innovation accelerator and pipeline conduit for womens health-focused commercial-stage companies, said Mr. Matz. I am delighted to lend my expertise to the organization and join the board of directors to help unlock value from Darés diverse portfolio of novel womens health products.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for womens reproductive and sexual health. The companys mission is to identify, develop and bring to market a portfolio of novel, differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women in the areas of contraception, vaginal health, sexual health, and fertility.
Darés product portfolio includes two potential first-in-class candidates currently in clinical development: Ovaprene®, a non-hormonal, monthly contraceptive vaginal ring, and Topical 5% Sildenafil Citrate Cream, a potential treatment for female sexual arousal disorder utilizing the same active ingredient as Viagra®. To learn more about Darés full portfolio of womens health products, and mission to deliver novel therapies for women, please visit www.darebioscience.com.
Daré may announce material information about its finances, product candidates, clinical trials and other matters using its investor relations website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré uses these channels to communicate with its investors and the public about the company and other issues. The information Daré posts on its investor relations website may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts on its investor relations website.
Investors on behalf of Daré Bioscience, Inc.:
Media on behalf of Daré Bioscience, Inc.: